3 Key Takeaways
Plain English Summary- 01Core Finding
In Phase I, healthy adults were randomized to receive a single dose of AZD0292 (n =24) or placebo (n = 8) in 4 cohorts (100-2,000 mg) and followed for 61 days or 161 days in cohort 4.
- 02Study Evidence
Tested in a animal models + randomized controlled trial (n =24) at the Phase I/II stage.
- 03Practical Meaning
Early-stage human studies — dosing, durability, and rare side effects still require Phase III confirmation.
What This Means for You
These results support further clinical development of AZD0292 for reduction of exacerbations in BE with chronic P. aeruginosa colonization, with pharmacokinetics requiring confirmation in the target patient population.
The Discovery
Chronic Pseudomonas aeruginosa airway colonization in bronchiectasis (BE) is associated with frequent exacerbations. Bispecific antibody AZD0292, targeting P. aeruginosa Psl and PcrV, was engineered from gremubamab with a Fc N3Y substitution to extend half-life and is being developed to reduce exacerbations in BE with chronic P. aeruginosa colonization. Preclinical studies assessed opsonophagocytic killing and anti-cytotoxicity assays, repeat-dose toxicology with ex vivo pharmacodynamic analyses in cynomolgus monkeys, and pharmacokinetics in human FcRn transgenic mice. In Phase I, healthy adults were randomized to receive a single dose of AZD0292 (n =24) or placebo (n = 8) in 4 cohorts (100-2,000 mg) and followed for 61 days or 161 days in cohort 4. Endpoints included safety, pharmacokinetics, immunogenicity, and exploratory cytokine/complement assessments. AZD0292 demonstrated comparable functional activity to gremubamab, an approximately substantially lower clearance in transgenic mice, and retained anti-P. aeruginosa activity in cynomolgus monkey serum after repeated dosing. In Phase I, AZD0292 was generally well tolerated. Mild/moderate infusion-related reactions occurred only at higher doses and were managed with routine clinical measures. Transient cytokine increases were observed after dosing, with no meaningful complement activation. Pharmacokinetics were approximately dose-dependent but slightly less than dose-proportional across 100-2,000 mg. Geometric mean half-life ranged from 24 to 47 days, though estimates are provisional given small cohort sizes and limited follow-up. No treatment-emergent anti-drug antibodies were detected.
How It Works, Simply
This infectious disease research focuses on antibodies · Immune response. Researchers evaluated it using an animal models + Randomized controlled trial (n =24) at the Phase I/II stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
In Phase I, healthy adults were randomized to receive a single dose of AZD0292 (n =24) or placebo (n = 8) in 4 cohorts (100-2,000 mg) and followed for 61 days or 161 days in cohort 4.
- 02Study Evidence
Tested in a animal models + randomized controlled trial (n =24) at the Phase I/II stage.
- 03Practical Meaning
Early-stage human studies — dosing, durability, and rare side effects still require Phase III confirmation.
Key Numbers
Biological Mechanism & Study Design
Study Design & Cohort
Animal models + Randomized controlled trial
Animal models + Randomized controlled trial (n =24) · Phase I/II
Biological Pathway & Modality
Antibodies · Immune response
Intervention: Translational and phase I evaluation of AZD0292, a novel, half-life extended
Experimental Findings & Endpoints
Chronic Pseudomonas aeruginosa airway colonization in bronchiectasis (BE) is associated with frequent exacerbations.
Bispecific antibody AZD0292, targeting P. aeruginosa Psl and PcrV, was engineered from gremubamab with a Fc N3Y substitution to extend half-life and is being developed to reduce exacerbations in BE with chronic P. aeruginosa colonization. Preclinical studies assessed opsonophagocytic killing and anti-cytotoxicity assays, repeat-dose toxicology with ex vivo pharmacodynamic analyses in cynomolgus monkeys, and pharmacokinetics in human FcRn transgenic mice.
In Phase I, healthy adults were randomized to receive a single dose of AZD0292 (n =24) or placebo (n = 8) in 4 cohorts (100-2,000 mg) and followed for 61 days or 161 days in cohort 4. Endpoints included safety, pharmacokinetics, immunogenicity, and exploratory cytokine/complement assessments.
AZD0292 demonstrated comparable functional activity to gremubamab, an approximately substantially lower clearance in transgenic mice, and retained anti-P. aeruginosa activity in cynomolgus monkey serum after repeated dosing. In Phase I, AZD0292 was generally well tolerated.
Mild/moderate infusion-related reactions occurred only at higher doses and were managed with routine clinical measures. Transient cytokine increases were observed after dosing, with no meaningful complement activation.
Pharmacokinetics were approximately dose-dependent but slightly less than dose-proportional across 100-2,000 mg. Geometric mean half-life ranged from 24 to 47 days, though estimates are provisional given small cohort sizes and limited follow-up.
No treatment-emergent anti-drug antibodies were detected.
Clinical Translation & Practice Context
These results support further clinical development of AZD0292 for reduction of exacerbations in BE with chronic P. aeruginosa colonization, with pharmacokinetics requiring confirmation in the target patient population.
The Bottom Line · Clinical Pearl
“These results support further clinical development of AZD0292 for reduction of exacerbations in BE with chronic P. aeruginosa colonization, with pharmacokinetics requiring confirmation in the target patient population.”
Published in The Journal of Infectious Diseases · Current Stage: Phase I/II